$ELTX

Here we go again, two insider buys in small biotech names that rocketed 43% and 76% last week.  This didn’t happen in a vacuum. For the last two months or so,  the daily top 50 largest percentage gainers and losers are filled with small-cap and bulletin board names you’ve never heard of, ripping up and down 40%-150% in a shark-like blood-infested feeding frenzy. The list is composed mostly of obscure biotech stocks, pre-revenue or little revenue shells, SPACS, and cryptocurrency names, scams, and fantasies inspired by occasional real biotech transactions, the most notable being the 273% premium Sanofi paid for … Read more